PURPOSE: The combination of left atrial appendage (LAA) occlusion with pulmonary vein isolation (PVI) potentially represents a comprehensive treatment for atrial fibrillation (AF), controlling symptoms while at the same time reducing the risk of stroke and the need for chronic anticoagulation. The aim of this randomized clinical trial was to assess the impact of LAA closure added to PVI in patients with high-risk AF. METHODS:Patients with a history of symptomatic paroxysmal or persistent AF refractory to ≥ 2 antiarrhythmic drugs, CHA2DS2-VASc score ≥ 2, and HAS-BLED score ≥ 3 were randomized to PVI-only (n = 44) orPVI with LAA closure (n = 45). RESULTS: Six patients in PVI + LAA closure group crossed over to PVI-only group due to failure of LAA closure device implantation. On-treatment comparisons at the 24 month follow-up revealed that 33 (66%) of the 50 PVI group and 23 (59%) of the 39 PVI with LAA closure group were AF-free on no antiarrhythmic drugs (p = 0.34). The PVI + LAA closure treatment was significantly associated with a higher AF burden during the blanking period: 9.7 ± 10.8 vs 4.2 ± 4.1% (p = 0.004). At the end follow-up, there were no serious complications and no strokes or thromboembolic events in either group. CONCLUSIONS: The combination of LAA closure device implantation with PVI was safe but was not observed to influence the success of PVI in patients with symptomatic refractory AF. Early AF after ablation, however, is increased by LAA closure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01695824.
RCT Entities:
PURPOSE: The combination of left atrial appendage (LAA) occlusion with pulmonary vein isolation (PVI) potentially represents a comprehensive treatment for atrial fibrillation (AF), controlling symptoms while at the same time reducing the risk of stroke and the need for chronic anticoagulation. The aim of this randomized clinical trial was to assess the impact of LAA closure added to PVI in patients with high-risk AF. METHODS:Patients with a history of symptomatic paroxysmal or persistent AF refractory to ≥ 2 antiarrhythmic drugs, CHA2DS2-VASc score ≥ 2, and HAS-BLED score ≥ 3 were randomized to PVI-only (n = 44) or PVI with LAA closure (n = 45). RESULTS: Six patients in PVI + LAA closure group crossed over to PVI-only group due to failure of LAA closure device implantation. On-treatment comparisons at the 24 month follow-up revealed that 33 (66%) of the 50 PVI group and 23 (59%) of the 39 PVI with LAA closure group were AF-free on no antiarrhythmic drugs (p = 0.34). The PVI + LAA closure treatment was significantly associated with a higher AF burden during the blanking period: 9.7 ± 10.8 vs 4.2 ± 4.1% (p = 0.004). At the end follow-up, there were no serious complications and no strokes or thromboembolic events in either group. CONCLUSIONS: The combination of LAA closure device implantation with PVI was safe but was not observed to influence the success of PVI in patients with symptomatic refractory AF. Early AF after ablation, however, is increased by LAA closure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01695824.
Authors: Claude S Elayi; Tamer S Fahmy; Oussama M Wazni; Dimpi Patel; Walid Saliba; Andrea Natale Journal: Heart Rhythm Date: 2006-06-15 Impact factor: 6.343
Authors: Jonathan S Steinberg; Rachel Palekar; Tina Sichrovsky; Aysha Arshad; Mark Preminger; Dan Musat; Richard E Shaw; Suneet Mittal Journal: Heart Rhythm Date: 2014-02-04 Impact factor: 6.343
Authors: Luigi Di Biase; J David Burkhardt; Prasant Mohanty; Javier Sanchez; Sanghamitra Mohanty; Rodney Horton; G Joseph Gallinghouse; Shane M Bailey; Jason D Zagrodzky; Pasquale Santangeli; Steven Hao; Richard Hongo; Salwa Beheiry; Sakis Themistoclakis; Aldo Bonso; Antonio Rossillo; Andrea Corrado; Antonio Raviele; Amin Al-Ahmad; Paul Wang; Jennifer E Cummings; Robert A Schweikert; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Pietro Santarelli; William R Lewis; Andrea Natale Journal: Circulation Date: 2010-07-06 Impact factor: 29.690
Authors: Nitish Badhwar; Dhanunjaya Lakkireddy; Mitsuharu Kawamura; Frederick T Han; Sivaraman K Iyer; Brian S Moyers; Thomas A Dewland; Chris Woods; Ryan Ferrell; Jayant Nath; Mathew Earnest; Randall J Lee Journal: J Cardiovasc Electrophysiol Date: 2015-04-29
Authors: Vivek Y Reddy; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Jonathan L Halperin; David Holmes Journal: Circulation Date: 2013-01-16 Impact factor: 29.690
Authors: Emanuele Bertaglia; Claudio Tondo; Antonio De Simone; Franco Zoppo; Massimo Mantica; Pietro Turco; Assunta Iuliano; Giovanni Forleo; Vincenzo La Rocca; Giuseppe Stabile Journal: Europace Date: 2009-11-03 Impact factor: 5.214
Authors: David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2014-07-08 Impact factor: 24.094
Authors: David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick Journal: Lancet Date: 2009-08-15 Impact factor: 79.321
Authors: Karen P Phillips; Evgeny Pokushalov; Aleksandr Romanov; Sergey Artemenko; Richard J Folkeringa; Tamas Szili-Torok; Gaetano Senatore; Kenneth M Stein; Omar Razali; Nicole Gordon; Lucas V A Boersma Journal: Europace Date: 2018-06-01 Impact factor: 5.214